

Takeda inks evaluation agreement with Elektrofi

23 September 2020 | News

Takeda to evaluate Elektrofi's formulation capabilities for plasma protein therapeutics



Elektrofi, a US based biotechnology company focused on drug formulation and delivery innovations, has announced it has entered into an evaluation agreement with Japanese firm Takeda Pharmaceutical for the potential use of the company's high concentration delivery technology.

Under the agreement, Takeda will evaluate Elektrofi's microparticle-based formulation technology using a non-disclosed plasma protein for the purpose of engineering high-concentration, low-viscosity samples.

Initially, Takeda will evaluate the storage stability and particle properties of protein microparticles produced using Elektroject, and will evaluate stability and formulations with high protein concentrations of the target protein. Financial terms of the agreement and milestones are not being disclosed.

By developing a breakthrough formulation platform technology, Elektrofi is addressing the long-standing and unmet need for stabilized, highly concentrated biologics through a proprietary microparticle technology. The technology enables patient-friendly small-volume injections for monoclonal antibodies, therapeutic proteins, and other large molecule drugs that are of growing importance to human health. It has the potential to drastically alter the treatment landscape for patients across a variety of disease areas and indications.